New pill aims to boost blood health in thalassemia patients
NCT ID NCT03692052
Summary
This study tested an oral medication called AG-348 in 20 adults with a form of thalassemia that doesn't require regular blood transfusions. The main goal was to see if the pill could safely and effectively raise hemoglobin levels, which carry oxygen in the blood. Participants took the drug for an initial 24-week period, with the option to continue in a long-term extension study for up to 10 years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Β-THALASSEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Imperial College Healthcare NHS Trust (Hammersmith Hospital)
London, W12 0HS, United Kingdom
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
UCSF Benioff Children's Hospital Oakland
Oakland, California, 94609, United States
-
University Health Network (Toronto General Hospital)
Toronto, Ontario, M5G 2C4, Canada
Conditions
Explore the condition pages connected to this study.